Actively Recruiting
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Led by AIO-Studien-gGmbH · Updated on 2025-02-18
12400
Participants Needed
1
Research Sites
626 weeks
Total Duration
On this page
Sponsors
A
AIO-Studien-gGmbH
Lead Sponsor
A
AstraZeneca
Collaborating Sponsor
AI-Summary
What this Trial Is About
Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany
CONDITIONS
Official Title
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 63 18 years
- Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
- Confirmed non-small cell lung cancer (NSCLC) or confirmed small cell lung cancer (SCLC)
- For metastatic NSCLC: Stage IV or stage IIIB/C (UICC8) if not eligible for curative surgery or radiochemotherapy
- For metastatic NSCLC: Informed consent no later than four weeks after start of first-line systemic treatment or diagnosis if receiving best supportive care only
- For early-stage NSCLC (Stage I, II, IIIA, or IIIB/C UICC8): Informed consent no later than four weeks after start of first anti-tumor treatment or diagnosis if receiving best supportive care only
- For early-stage NSCLC: Systemic chemotherapy, radiation therapy, surgery, or best supportive care
- For SCLC: Informed consent no later than four weeks after start of first anti-tumor treatment or diagnosis if receiving best supportive care only
- For SCLC: Systemic chemotherapy, radiation therapy, surgery, or best supportive care
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pius-Hospital
Oldenburg, Germany, 26121
Actively Recruiting
Research Team
A
Annika Groth
CONTACT
P
Paula Ludwig
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here